336 related articles for article (PubMed ID: 1850862)
1. [Platelet-activating factor (PAF) antagonists].
Terasawa M
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
[No Abstract] [Full Text] [Related]
2. Hetrazepine PAF antagonists.
Ikegami K; Meade CJ; Heuer HO; Birke F
J Lipid Mediat; 1992; 5(2):177-82. PubMed ID: 1326346
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
4. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
[TBL] [Abstract][Full Text] [Related]
5. Presence of specific platelet-activating factor binding-sites in neuroblastoma N1E-115 cells.
Lalouette F; Diserbo M; Martin C; Verdetti J; Fatome M
Neurosci Lett; 1995 Feb; 186(2-3):173-6. PubMed ID: 7777190
[TBL] [Abstract][Full Text] [Related]
6. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
[TBL] [Abstract][Full Text] [Related]
7. Presence of specific platelet-activating factor binding sites in the rat retina.
Thierry A; Doly M; Braquet P; Cluzel J; Meyniel G
Eur J Pharmacol; 1989 Apr; 163(1):97-101. PubMed ID: 2545464
[TBL] [Abstract][Full Text] [Related]
8. Specific binding sites of platelet activating factor on the intact bovine cerebral microvascular endothelial cells and antagonism of drugs.
Sun DX; Rui YC; Zeng GQ; Zhu J; Shen YA
Zhongguo Yao Li Xue Bao; 1992 Jul; 13(4):326-9. PubMed ID: 1333718
[TBL] [Abstract][Full Text] [Related]
9. Species-dependent differences of high affinity [3H]PAF-binding to platelets from humans and pigs and its inhibition by selected antagonists.
Ostermann G; Lorenz A; Hofmann B; Kertscher HP
J Lipid Mediat; 1991 Nov; 4(3):289-98. PubMed ID: 1662546
[TBL] [Abstract][Full Text] [Related]
10. Species difference in the specific receptors of platelet activating factor.
Hwang SB; Lam MH
Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
[TBL] [Abstract][Full Text] [Related]
11. PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists.
Dive G; Godfroid JJ; Lamotte-Brasseur J; Batt JP; Heymans F; Dupont L; Braquet P
J Lipid Mediat; 1989; 1(4):201-15. PubMed ID: 2562434
[TBL] [Abstract][Full Text] [Related]
12. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex.
Marcheselli VL; Rossowska MJ; Domingo MT; Braquet P; Bazan NG
J Biol Chem; 1990 Jun; 265(16):9140-5. PubMed ID: 2160958
[TBL] [Abstract][Full Text] [Related]
13. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
[TBL] [Abstract][Full Text] [Related]
14. Platelet-activating factor induces cell death in cultured astrocytes and oligodendrocytes: involvement of caspase-3.
Hostettler ME; Knapp PE; Carlson SL
Glia; 2002 May; 38(3):228-39. PubMed ID: 11968060
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation.
Kato K; Clark GD; Bazan NG; Zorumski CF
Nature; 1994 Jan; 367(6459):175-9. PubMed ID: 8114914
[TBL] [Abstract][Full Text] [Related]
16. PAF antagonists as possible inhibitors of corneal epithelial defects and ulceration.
Bazan HE; Tao Y
J Ocul Pharmacol Ther; 1997 Jun; 13(3):277-85. PubMed ID: 9185044
[TBL] [Abstract][Full Text] [Related]
17. [Phospholipid thrombocyte activating factor, its analogs and antagonists: prospects of their use in medicine].
Kulikov VI; Muzia GI
Vestn Akad Med Nauk SSSR; 1991; (10):13-7. PubMed ID: 1801455
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
19. From ginkgolides to N-substituted piperidino-thieno diazepines, a new series of highly potent dual antagonists.
Braquet P; Laurent JP; Rolland A; Martin C; Pommier J; Hosford D; Esanu A
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():929-37. PubMed ID: 1825436
[No Abstract] [Full Text] [Related]
20. Ginkgolides and platelet-activating factor binding sites.
Hosford DJ; Domingo MT; Chabrier PE; Braquet P
Methods Enzymol; 1990; 187():433-46. PubMed ID: 2172741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
